Mumbai: Officials of pharmaceutical company Ipca Laboratories Ltd on Monday said that it will, together with the Central Drug Research Institute (CDRI), develop a synthetic substitute for anti-malarial drugs, based on Artemisinin.
The pharma company has entered into a collaborative-licence agreement with CDRI for further development of its compound 99/411—a synthetic substitute for drugs based on Artemisinin derived from the plant artemisia annua, Ipca informed the Bombay Stock Exchange (BSE).
It would be a major breakthrough in the cost-effective treatment of multi-drug resistant falciparum malaria in clinical practice, Ipca officials said.
The compound, which is under licensing, is being developed in oral form to meet the new global challenges of malaria incidence, including in India.
Artemisinin-based combination therapy has been recommended by the World Health Organization for treating falciparum malaria.
Lucknow-based CDRI is a research wing of the Union government-run Council of Scientific and Industrial Research (CSIR).
Mumbai-based Ipca produces and exports a wide range of anti-malarial drugs such as choloroquine and amodiaquine.